News

BCX4430 is an RNA dependent-RNA polymerase inhibitor that has showed broad-spectrum activity in vitro against more than 20 RNA viruses in nine different families such as filoviruses, togaviruses,

Amlodipine and Valsartan Tablets are the generic version of Swiss pharmaceutical firm Novartis’ Exforge Tablets. The US Food and Drug Administration (FDA) has also granted approval for the

Both Actavis Australia and Amneal have agreed to work expeditiously to complete the transaction and aim to prevent disruption of supply to existing purchasers of Actavis’ products. Until

Under the deal, Broad Institute and Bayer will collaborate on cardiovascular genomics, genetic discovery, target validation, and drug discovery activities. A joint steering committee and joint research committee

The deal, funded through a combination of cash, debt and equity, includes the assumption of €1.3bn in debt. The acquisition will expand Perrigo’s market presence in Europe and

Syndax’s entinostat is an oral, highly selective histone deacetylase (HDAC) inhibitor, while Keytruda is Merck’s first anti-PD-1 therapy approved in the US. Keytruda is a humanized monoclonal antibody

The approval will allow the company to expand its Phase II OCCC trial currently underway in multiple centers in North America with Princess Margaret Cancer Centre in Canada

Aduro is focused on the discovery and development of next generation cancer immunotherapies targeting the Stimulator of Interferon Genes (STING) pathway. The Swiss firm has also launched a

The deal advances Merck Serono’s science-driven strategy to develop new therapies that modulate the immune system’s natural ability to fight tumors. As part of the deal, Intrexon will